Data on the volunteers were reviewed by the Data Safety Monitoring Board (DSMB). No adverse events or changes in blood counts, BUN or transaminase were reported. The DSMB judged the vaccine to be safe permitting the studies to continue in infants. Phase 2 was a dose and schedule ranging study, conducted at 12 medical centers in Thanh Son district, Phu Tho provinces from November 2009 through April 2010. Doxorubicin nmr Infants 6–12 weeks of age were eligible for inclusion in the study if they were born at full term (38 weeks) and were free of obvious health

problem. Infants were excluded if they were immunocompromised, had a history of allergic reaction to any vaccine components or had received vaccines against rotavirus or were involved in any other vaccine

trials at the same time. Infants (n = 200) were randomly assigned to 5 groups (40 infants/group) ( Fig. 1). Two groups received 2 oral doses of Rotavin-M1 in 1 of 2 titers – 106.0 or 106.3 FFU at 6–12 weeks of age (for the first dose) and 2 months later for the second dose (groups 2L and 2H), respectively. These 2 vaccine titers were also given to infants on a 3-dose schedule, beginning at 6–12 weeks of age for the first dose and 1 month and 2 months later for the 2nd click here and 3rd doses (groups 3L and 3H, respectively). Rotarix™ was used as the vaccine control and was given to 40 infants at 6–12 weeks of age and 1 month later (Group Rotarix™). GSK recommends that the first dose of Rotarix™ be started between 6 and 14 weeks of age and that the second dose be separated by at least 1 month. The vaccine recipients, the parents/guardians,

the laboratory staff, the field teams and working doctors did not know the coding assignment of these groups. Other vaccines (BCG, oral polio Casein kinase 1 vaccine, Diphtheria–Tetanus–Pertussis and hepatitis B) used in the country’s Expanded Program of Immunization (EPI) were administered normally to these infants on different days (10–20 days before or after rotavirus vaccine was administered). Serum samples were obtained for testing levels of anti-rotavirus IgA and IgG antibody on the day that the first dose was administered and 1 month after the second or third dose. In addition, serum samples were also obtained from groups that received 3 doses of vaccine (groups 3L and 3H) immediately before the 3rd dose (Fig. 1). Each blood sample from a child was collected in 2 tubes, one with anti-coagulant (EDTA) (whole blood) and one without anti-coagulant (serum). Serum and whole blood samples were immediately transferred to the provincial hospital for analysis of blood cell counts (red blood cells, white blood cells and platelet), transaminase levels (aspartate aminotransferase, AST and alanine aminotransferase, ALT) and BUN within 4 h after collection.